Notice of Results

RNS Number : 0948E

Renalytix AI PLC

26 February 2020

 

Renalytix AI plc

("RenalytixAI", the "Company" or the "Group")

Notice of results

Investor briefing

Renalytix AI plc (LSE : RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020.

Investor briefing

A briefing open to all investors will take place on Monday 9 March 2020 at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW from 5.15pm for a 5.30pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email  [e-mail]

For further information, please contact:

Renalytix AI plc		www.renalytixai.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker)		Tel: [phone]
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker)			Tel: [phone]
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease.  It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

For more information, visit  renalytixai.com

 

END

 

 

NORSEMFIIESSESE